Research on Severe Asthma
The French Society for Respiratory diseases (SPLF), through its Asthma and Allergy working group (G2A), wishes to set up a national cohort of severe asthma patients to describe this population and the use of step 4 and 5 treatment. This study also meets the demand for post - registration studies required by the Health Authorities for biotherapies and bronchial thermoplasty. Other European or international cohorts of asthmatic patients exist and RAMSES could contribute to data sharing initiatives.
‣ \- Patient with severe asthma : Meeting the definition of ATS-ERS: which requires a combination of high dose CSI and B2LDA.
‣ Or receiving level 5 support (initiating treatment or already treated) :
• Long-term oral corticosteroids (\> 6 months in the year prior to inclusion)
• And / or monoclonal antibody
• And / or bronchial thermoplasty
• And / or other complex costs corresponding to the level 5 treatments
⁃ Consultant or hospitalized in one of the centers participating in RAMSES study